1-10 of 10
Ashutosh Wechalekar, MD, FRCPath
Close
Sort by
Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Efstathios Kastritis, MD, Xavier Leleu, Bertrand Arnulf, MD, Elena Zamagni, María Teresa Cibeira, MD, Fiona Kwok, FRACP, FRCPA, MBBS, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Roman Hajek, MD, Philippe Moreau, Arnaud Jaccard, MD PhD, Stefan Schönland, MD, Robin Filshie, PhD FRACP FRCPA, Emmanuelle Nicolas-Virelizier, MD, Bradley Augustson, Maria-Victoria Mateos, MD PhD, Ashutosh Wechalekar, MD FRCPath, Eric Hachulla, MD PhD, Paolo Milani, MD, Meletios A Dimopoulos, Jean-Paul Fermand, Andrea Foli, MD, Maria Gavriatopoulou, Antonio Palumbo, MD, Pieter Sonneveld, MD PhD, Hans Erik Johnsen, MD DMSc, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD
Journal: Blood
Blood (2016) 128 (22): 646.
https://doi.org/10.1182/blood.V128.22.646.646
Published: 2016
Journal Articles

Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study

Ashutosh Wechalekar, MD FRCPath, Darren Foard, Carol Whelan, MD FRCP, Mariana Fontana, Thirusha Lane, RN MSc, Candida Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MD FRCP, Julian D Gillmore, MD PhD FRCP, Philip N Hawkins, MD PhD FMedSci
Journal: Blood
Blood (2016) 128 (22): 4511.
https://doi.org/10.1182/blood.V128.22.4511.4511
Published: 2016
Journal Articles

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MDFRCP, Helen Lachmann, MDFRCP, Marianna Fontana, MD, Shameem Mahmood, FRCPath, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci
Journal: Blood
Blood (2015) 126 (23): 732.
https://doi.org/10.1182/blood.V126.23.732.732
Published: 2015
Journal Articles

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MD, Sajitha Sachchithanantham, MRCP, FRCPath, Marianna Fontana, MD, Shameem Mahmood, MRCP. FRCPath, Darren Foard, RN, Thirusha Lane, RN, Helen J Lachmann, MD FRCP, Julian D Gillmore, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci
Journal: Blood
Blood (2014) 124 (21): 3485.
https://doi.org/10.1182/blood.V124.21.3485.3485
Published: 2014
Journal Articles

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Shameem Mahmood, MRCP. FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontana, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath
Journal: Blood
Blood (2013) 122 (21): 1981.
https://doi.org/10.1182/blood.V122.21.1981.1981
Published: 2013
Journal Articles

Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis

Brian A Walker, PhD, Dorota Rowczienio, MSc, Eileen M Boyle, MD, Christopher P Wardell, PhD, Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Julian D Gillmore, MD, Shameem Mahmood, MRCP. FRCPath, Helen J Lachmann, MD, FRCP, Philip N Hawkins, Faith E Davies, MD, Gareth J Morgan, MD PhD, Ashutosh Wechalekar, MD, FRCPath
Journal: Blood
Blood (2013) 122 (21): 3098.
https://doi.org/10.1182/blood.V122.21.3098.3098
Published: 2013
Journal Articles

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Dorota Rowczenio, Shameem Mahmood, MRCP, FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath
Journal: Blood
Blood (2013) 122 (21): 3120.
https://doi.org/10.1182/blood.V122.21.3120.3120
Published: 2013
Journal Articles

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Shameem Mahmood, MRCP. FRCPath, Sajitha Sachchithanantham, MRCP. FRCPath, Frank Bridoux, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontanna, MD, Carol Whelan, MD, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath
Journal: Blood
Blood (2013) 122 (21): 3143.
https://doi.org/10.1182/blood.V122.21.3143.3143
Published: 2013
Journal Articles

Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.

Shameem Mahmood, MBBCh. FRCPath, Christopher P. Venner, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath
Journal: Blood
Blood (2012) 120 (21): 2978.
https://doi.org/10.1182/blood.V120.21.2978.2978
Published: 2012
Journal Articles

Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases

Helen J Lachmann, MD, FRCP, Stephen Harding, PhD, Ashutosh Wechalekar, MD, FRCPath, Julian D Gillmore, E. Nicole Amft, MD, PhD, FRCP, Philip N Hawkins
Journal: Blood
Blood (2010) 116 (21): 3958.
https://doi.org/10.1182/blood.V116.21.3958.3958
Published: 2010